Serum adrenal androgens in hyperprolactinaemic women prior to, during, and after chronic treatment with bromocriptine

1982 ◽  
Vol 101 (2) ◽  
pp. 235-241 ◽  
Author(s):  
William S. Evans ◽  
Rick J. Schiebinger ◽  
Donald L. Kaiser ◽  
Wallace C. Nunley ◽  
D. Lynn Loriaux ◽  
...  
Keyword(s):  
Clinical Features ◽  
Polycystic Ovary ◽  
Serum Levels ◽  
Normal Range ◽  
Adrenal Androgen ◽  
Ovary Syndrome ◽  
Adrenal Androgens ◽  
Dopaminergic Drugs ◽  
The Mean ◽  
A Prospective Study

Abstract. Conflicting data exist in the literature regarding serum adrenal androgen concentrations in hyperprolactinaemic states and the influence or lack thereof of dopaminergic drugs on the androgens. We carried out a prospective study on 7 hyperprolactinaemic women, none of whom had clinical features commonly associated with elevated androgens. Serum levels of prolactin (Prl), cortisol, androstenedione, dehydroepiandrosterone (DHA) and dehydroepiandrosterone sulphate (DHAS) were measured basally, at 3, 6, and 12 months during chronic bromocriptine therapy, and 2 months following withdrawal of the drug. Prior to bromocriptine therapy, and despite a mean serum Prl of 178 ng/ml, all values of cortisol, androstenedione and DHA were normal as were 6 of 7 DHAS values. During treatment with bromocriptine for 12 months, the mean Prl level dropped into the normal range, but levels of cortisol, androstenedione and DHA remained unchanged. DHAS was significantly lower at 12 months when compared to initial levels but was not significantly different at 3 and 6 months. No significant differences were observed in cortisol or androgens 2 months after termination of the bromocriptine compared to basal levels. A significant correlation was observed between cortisol and both androstenedione (P = 0.0042) and DHA (P = 0.0002) but not with DHAS. A significant correlation was found to exist between Prl and DHAS (P < 0.0001) but not with androstenedione or DHA. Thus, we found normal levels of serum adrenal androgens in 6 of 7 hyperprolactinaemic women, none of whom demonstrated clinical features of the polycystic ovary syndrome. These data suggest: 1) increased basal adrenal androgens in hyperprolactinaemia may not be as common as previously reported; 2) androstenedione and DHA do not correlate with Prl; 3) DHAS is correlated with Prl. Although it appears that DHAS and prolactin concentrations are related, the mechanism underlying this relationship remains uncertain.

scholarly journals Association Between the -1031 (T/C) Polymorphism of TNF-α Gene and Biochemical Factors in Women With Polycystic Ovary Syndrome

2020 ◽  
Vol 24 (6) ◽  
pp. 486-497
Author(s):  
Mehdi Sahmani ◽  
◽  
Talaate Dabaghi Ghaleh ◽  
Maryam Yargholi ◽  
Farshad Foroghi ◽  
...  
Keyword(s):  
Regression Analysis ◽  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Serum Levels ◽  
Inflammatory Factor ◽  
Ovary Syndrome ◽  
Healthy Women ◽  
Tnf Α ◽  
The Mean ◽  
The Relationship

Background: Tumor Necrosis Factor Alpha (TNF-α) gene, as an inflammatory factor, plays an important role in reproductive physiology, especially in women with Polycystic Ovary Syndrome (PCOS). Objective: This study aims to investigate the relationship between the -1031 T/C polymorphism of TNF-α gene and biochemical factors in women with PCOS. Methods: In this case-control study, participants were 106 women with PCOS and 114 healthy women referred to Kosar Hospital in Qazvin, Iran. The TNF-α gene’s polymorphism was determined using Polymerase Chain Reaction (PCR) technique and PCR-Restriction Fragment Length Polymorphism (PCR-RFLP) method. Biochemical factors of serum levels were also measured in two groups. Logistic regression analysis examined the relationship between the frequency of alleles in different states and the risk of PCOS. Findings: There were statistically significant difference in the mean levels of total cholesterol, triglycerides, testosterone, two-hour blood glucose and body mass index between the groups, whose values were higher in women with PCOS compared to healthy women (P<0.001). In women with PCOS, the mean serum levels of triglyceride and high-density lipoprotein were significantly different between the three TT, CC, TC genotypes of TNF-α gene polymorphism (P<0.05). The results of regression analysis showed that the TT genotype had significant association with the risk of PCOS (OR=2.43, P=0.006, 95%CI: 1.28-2.62). Conclusion: It seems that there is a relationship between the -1301 (T/C) polymorphism of TNF-α gene and the risk of PCOS in women.

Prolactin secretion in polycystic ovary syndrome (PCO): correlation with the steroid pattern

1984 ◽  
Vol 105 (1) ◽  
pp. 99-104 ◽  
Author(s):  
Enrico Carmina ◽  
Francesca Rosato ◽  
Michele Maggiore ◽  
Anna Maria Gagliano ◽  
Daniela Indovina ◽  
...  
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Serum Levels ◽  
Prolactin Secretion ◽  
Normal Range ◽  
Ovary Syndrome ◽  
Trh Stimulation ◽  
Baseline Conditions

Abstract. To evaluate the prevalence of hyperprolactinaemia in PCO patients and its possible correlation with a steroid pattern, we studied prolactin secretion (basal and after TRH stimulation) in 40 women affected by typical PCO. LH, FSH, testosterone, oestradiol, oestrone, DHEA-s and 17-OHP serum levels were also evaluated. Twenty-one patients had prolactin (Prl) values in the normal range both in baseline conditions and after TRH stimulation; 10 patients had normal basal values of Prl but an exaggerated response to TRH stimulation; 9 patients had high Prl basal values and an exaggerated response to TRH. The presence of hyperprolactinaemia was associated with increased serum levels of oestrone (P < 0.01), DHEA-s (P < 0.01) and 17-OHP (P < 0.05). In conclusion, hyperprolactinaemia is as relatively frequent condition which affects almost half the patients suffering from PCO and is probably related to an increase of serum oestrogens, mostly oestrone. Moreover, in patients with PCO and hyperprolactinaemia, the production of some other steroids is also affected.

scholarly journals Physical Performance Regarding Handgrip Strength in Women with Polycystic Ovary Syndrome

2020 ◽  
Vol 42 (12) ◽  
pp. 811-819
Author(s):  
Gislaine Satyko Kogure ◽  
Victor Barbosa Ribeiro ◽  
Flávia Ganoa de Oliveira Gennaro ◽  
Rui Alberto Ferriani ◽  
Cristiana Libardi Miranda-Furtado ◽  
...  
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Physical Performance ◽  
Lean Mass ◽  
Polycystic Ovary ◽  
Handgrip Strength ◽  
Serum Levels ◽  
Total Testosterone ◽  
Dominant Hand ◽  
Ovary Syndrome ◽  
Pcos Group

Abstract Objective The present study aimed to investigate the physical performance of handgrip strength (HGS) in women with polycystic ovary syndrome (PCOS). Methods A case-control study that included 70 women with PCOS and 93 age-matched healthy women aged between 18 and 47 years with body mass index (BMI) between 18 Kg/m2–39.9 Kg/m2. The serum levels of total testosterone, androstenedione, insulin, estradiol, thyroid-stimulating hormone (TSH), prolactin, sex hormone-binding globulin (SHBG), and 17-hydroxyprogesterone (17-OHP) were measured. The free androgen index (FAI) and the homeostatic model assessment of insulin resistance (HOMA-IR) were calculated. The body composition regions of interest (ROIs) were assessed by dual-energy X-ray absorptiometry (DXA), and the handgrip strength (HGS) was evaluated for both the dominant and the non-dominant hands with a manual Sammons Preston (Bolingbrook, IL, US) bulb dynamometer. Results Women with PCOS had high serum levels of total testosterone (p < 0.01), androstenedione (p = 0.03), and insulin (p < 0.01), as well as high FAI (p < 0.01) and HOMA-IR (p = 0.01) scores. Compared with the non-PCOS group, the PCOS group had greater total lean mass in the dominant hand (p < 0.03) and greater HGS in both the dominant and the non-dominant hands (p < 0.01). The HGS was correlated with lean mass (p < 0.01). Conclusion Women with PCOS have greater HGS. This may be associated with age and BMI, and it may be related to lean mass. In addition, the dominance effect on muscle mass may influence the physical performance regarding HGS in women with PCOS.

scholarly journals Association of CYP3A7*1C and Serum Dehydroepiandrosterone Sulfate Levels in Women with Polycystic Ovary Syndrome

2008 ◽  
Vol 93 (7) ◽  
pp. 2909-2912 ◽  
Author(s):  
Mark O. Goodarzi ◽  
Ning Xu ◽  
Ricardo Azziz
Keyword(s):  
Los Angeles ◽  
Polycystic Ovary Syndrome ◽  
White Women ◽  
Polycystic Ovary ◽  
Medical Center ◽  
Free Testosterone ◽  
Total Testosterone ◽  
Adrenal Androgen ◽  
Androgen Excess ◽  
Ovary Syndrome

Abstract Context: Adrenal androgen excess is common in polycystic ovary syndrome (PCOS) and appears to be heritable. CYP3A7 metabolizes dehydroepiandrosterone and its sulfate (DHEAS). A promoter variant, CYP3A7*1C, which results in persistent expression in adults, was associated with reduced DHEAS levels in a previous study, which led us to consider CYP3A7*1C as a modulator of adrenal androgen excess in patients with PCOS. Objective: The objective was to replicate the association between CYP3A7*1C and reduced DHEAS levels in PCOS patients and assess its possible role in modulating testosterone levels. Design: Women with and without PCOS were genotyped for CYP3A7*1C, and this variant was tested for association with DHEAS and total and free testosterone. Setting: Subjects were recruited from the reproductive endocrinology clinic at the University of Alabama at Birmingham; controls were recruited from the surrounding community. Genotyping took place at Cedars-Sinai Medical Center (Los Angeles, CA). Participants: A total of 287 white women with PCOS and 187 controls were studied. Main Measurements: CYP3A7*1C genotype, PCOS risk, and androgen levels were measured. Results: PCOS subjects who carried the CYP3A7*1C variant had lower levels of serum DHEAS and total testosterone (P = 0.0006 and 0.046, respectively). The variant was not associated with PCOS risk. Conclusion: This study replicated prior work of the association of CYP3A7*1C and decreased DHEAS in a different population of young PCOS women, providing further genetic evidence that CYP3A7 plays a potential role in modulation of DHEAS levels. Adult expression of CYP3A7 may modify the PCOS phenotype by ameliorating adrenal androgen excess.

scholarly journals Shaoyao-Gancao Decoction alleviated hyperandrogenism in a letrozole-induced rat model of polycystic ovary syndrome by inhibition of NF-κB activation

2019 ◽  
Vol 39 (1) ◽  
Author(s):  
Yun-yun Shao ◽  
Zhuang-peng Chang ◽  
Yao Cheng ◽  
Xin-chun Wang ◽  
Jing-ping Zhang ◽  
...  
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Therapeutic Effect ◽  
Polycystic Ovary ◽  
Serum Levels ◽  
Underlying Mechanism ◽  
Chemical Components ◽  
Potential Mechanism ◽  
Ovary Syndrome ◽  
Ovarian Weight ◽  
Protein Levels

Abstract Shaoyao-Gancao Decoction (SGD) has been widely used for the treatment of gynopathy. The present study aimed to evaluate the therapeutic effect and potential mechanism of SGD on hyperandrogenism in polycystic ovary syndrome (PCOS) rats. In the present work, SGD was orally administrated to the PCOS rats at the dose of 12.5, 25, and 50 g/kg/d for 14 consecutive days. UPLC–MS/MS was performed to identify the main chemical components of SGD. Body weight, ovarian weight, cystic dilating follicles, and serum levels of steroid hormones were tested to evaluate the therapeutic effect of SGD. In order to further clarify the underlying mechanism, we also measured mRNA and the protein levels of NF-κB, NF-κB p65, P-NF-κB p65, and IκB by RT-qPCR and Western blotting techniques. Our results showed that SGD treatment significantly alleviated hyperandrogenism in PCOS rats as evidenced by reduced serum levels of T and increased E2 and FSH levels. In addition, SGD effectively reduced the phosphorylation of NF-κB p65 and increased the expression of IκB. Results of the present study demonstrated that SGD could ameliorate hyperandrogenism in PCOS rats, and the potential mechanism may relate to the NF-κB pathway.

scholarly journals Efficacy of letrozole versus clomiphene citrate for infertile women with polycystic ovary syndrome

2021 ◽  
Vol 10 (8) ◽  
pp. 2944
Author(s):  
Sinan S. Ay ◽  
Özer Birge ◽  
Mehmet S. Bakır ◽  
Ayşe E. Yumru
Keyword(s):  
Aromatase Inhibitor ◽  
Ovulation Induction ◽  
Polycystic Ovary ◽  
Clomiphene Citrate ◽  
Ovary Syndrome ◽  
Infertile Women ◽  
Appropriate Treatment ◽  
The Mean ◽  
Infertility Patients ◽  
Infertile Patients

Background: The aim was to compare ovulation induction protocols in anovulatory patients, who make up a significant percentage of infertility patients, and to determine the most appropriate treatment for patients in the clinic based on the findings.Methods: The effectiveness of clomiphene citrate (CC) and letrozole (aromatase inhibitor) in ovulation induction treatments were retrospectively compared in patients who applied for infertility in the last 5 years and were found to be anovulatory. 20 of these patients were being treated with clomiphene citrate, while the 18 were being treated with letrozole.Results: The study included a total of 38 anovulatory infertile patients. The mean age of the patients was found to be 29.3. When the endometrial thicknesses (ET) after the treatment were compared, the first group's mean EC was 6.1, while that of the second group was 9.05. The endometrial thicknesses measured after the treatments were found to be significantly different, which were consistent with other studies in the literature. Post-treatment ovulation responses were similar with 55% in both groups. In the evaluation of pregnancy outcomes, 20% of pregnancy was achieved in the first group and 33% in the second group.Conclusions: The use of letrozole, an aromatase inhibitor, may be suggested as an alternative to CC in the ovulation induction protocol in our clinical practice, particularly in obese patients.

Sign in / Sign up

Export Citation Format

Share Document